UBS analyst Dan Leonard lowered the firm’s price target on Danaher (DHR) to $240 from $275 and keeps a Buy rating on the shares. Danaher’s bioprocess recovery was partially offset by incremental weakness in life sciences, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DHR:
- Danaher price target lowered to $225 from $231 at Baird
- Danaher Receives Buy Rating Amid Strong Performance and Strategic Positioning
- Danaher Corporation Reports Strong Q1 2025 Results
- Danaher Corporation’s Earnings Call Highlights Achievements and Challenges
- Positive Outlook for Danaher: Strong Performance, Strategic Initiatives, and Increased Price Target Justify Buy Rating